Additionally, the company entered into an exclusive worldwide license agreement with Amgen for the development of a subcutaneous formulation of teprotumumab using Xeris' XeriJect technology in Thyroid Eye Disease (TED). Xeris reported a net loss of $19 million, or $0.14 per share, for the first quarter of 2024. However, the company showcased a strong financial position with cash, cash equivalents, and short-term investments totaling $87.4 million as of March 31, 2024, compared to $72.5 million at the end of December 2023.